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SYNOPSIS 
SHP-2 is essential for hematopoietic skeletal and vascular development. Thus, the identification of 
its binding partners is critically important. Here, we describe a unique monoclonal antibody, 
WM78, which interacts with PZR, a SHP-2 binding partner. Furthermore, we identify two novel 
isoforms of PZR, PZRa and PZRb, derived by differential splicing from a single gene transcription 
unit on human chromosome 1q24. All are type 1 transmembrane glycoproteins with identical 
extracellular and transmembrane domains, but differ in their cytoplasmic tails. The PZR 
intracellular domain contains two SHP-2 binding ITIM-motifs (VIY246AQL and VVY263ADI) 
which are not present in PZRa and PZRb. Using the WM78 monoclonal antibody (mAb) to the 
common extracellular domain of the PZR isoforms, we demonstrate that the PZR molecules are 
expressed on mesenchymal and hematopoietic cells, being present on the majority of CD34+CD38+ 
and early clonogenic progenitors and at lower levels on CD34+CD38- cells and the hierarchically 
more primitive pre-CFU. Interestingly, we show, by RT-PCR, that the PZR isoforms are 
differentially expressed in hematopoietic, endothelial and mesenchymal cells. Both PZR and PZRb 
are present in CD133+ precursors and endothelial cells, PZRb predominates in mesenchymal and 
committed myelomonocytic progenitor cells and all three isoforms occur in erythroid precursor cell 
lines. Importantly, using SHP-2 mutant (∆46-110) and SHP-2 rescue embryonic fibroblasts stably 
expressing the PZR isoforms, we demonstrate for the first time that PZR, but not PZRa or PZRb, 
facilitates fibronectin dependent migration of cells expressing a competent SHP-2 molecule. These 
observations will be instrumental in determining the mechanisms whereby PZR isoforms regulate 
cell motility. 
 
Key words: Immunoglobulin superfamily; CD34+; stem cells; function; genomic structure. 
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INTRODUCTION 
 
Complex processes such as cell growth, differentiation, and migration require the 
integration of multiple types of extracellular signals, including those delivered by growth factors, 
cytokines, cell adhesion molecules and extracellular matrix (ECM) proteins [1]. Most signaling 
pathways involve changes in cellular tyrosyl phosphorylation which are regulated by a diverse 
family of protein tyrosine kinases (PTKs) and an equally diverse family of protein tyrosine 
phosphatases (PTPs) [2].  SHP-1 and SHP-2 comprise a subfamily of tyrosine-specific cytoplasmic 
PTPs, with roles in hematopoiesis, bone formation and vasculogenesis [3-6] . Whilst SHP-1 and 
SHP-2 share approximately 60% overall sequence identity, contain two SH2 domains and a 
catalytic domain, they exhibit distinct physiological functions. SHP-1 is predominantly expressed 
in haematopoietic cells and is a negative regulator of phosphotyrosine signaling [7-9], whereas 
SHP-2 is ubiquitously expressed and is considered to be a positive mediator of hematopoiesis [4, 8, 
10, 11]. These molecules are cytoplasmic tyrosine phosphatases, each containing two unique SH2 
domains which bind to a distinct amino acid sequence surrounding a phosphotyrosine residue.   
Evidence for the functional importance of SHP-1 and SHP-2 comes from the analyses of 
shp-1 and shp-2 mutant knock-out organisms. SHP-1 motheaten (me) and motheaten viable (mev) 
[7] mice suffer from immune deficiency and autoimmune diseases and exhibit hematopoietic 
abnormalities, e.g. excessive erythropoiesis, augmented granulocyte and monocyte production and 
tissue accumulation, overexpansion of CD5+ B cells, leukocyte hypersensitivity and deregulated 
mast cell and defective T and NK cell functions [7, 10, 12]. In contrast, disruption of the mouse 
SHP-2 gene causes death of the embryos at midgestation, highlighting its importance in 
development. Moreover, fibroblasts from mice harbouring a deletion of SHP-2 exon 3, which 
express low levels of a defective SHP-2 protein that lacks its N-terminal SH2 domain [13] exhibit 
impaired mitogen-activated protein kinase (MAPK) activation in response to fibroblast growth 
factor (FGF), epidermal growth factor (EGF), and insulin-like growth factor I (IGF-I) [13, 14]. In 
other pathways, however, SHP-2 binds to distinct signaling intermediates. One class of SHP-2 
binding proteins, exemplified by the Drosophila daughter of sevenless (dos) gene product, consists 
of an N-terminal pleckstrin homology domain, multiple proline-rich stretches and potential tyrosyl 
phosphorylation sites [15]. A second class of molecules belonging to the Ig-ITIM 
(Immunoglobulin-Immunoreceptor Inhibitory Motif) family has been identified as SHP-2 binding 
proteins. SHP substrate 1 (SHPS-1) is a prototypical member of this class of receptors, of which 
there are now more than 30 proteins. This family is characterised by the presence of one or more 
ITIMs (comprising of 6 amino acids (I/V/L/S)xYxx(L/V)) in their cytoplasmic domain. The 
consensus motif is nearly always associated with a second tandem ITIM, separated from the first by 
a canonical 25-31 amino acid long spacer sequence [16]. SHPS-1 was initially identified as a SHP-
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2 binding protein, the tyrosyl phosphorylation of which is increased in cells expressing catalytically 
impaired SHP-2 mutants. 
In an attempt to identify additional substrates for SHP-2, Zhao and Zhao [17] overexpressed 
a catalytically inactive mutant of SHP-2 in HEK-293 cells. Following pervanadate stimulation, 
several hyper-tyrosine phosphorylated glycoproteins associated with SHP-2 were identified, 
including a 43-kD membrane protein [17].The protein was subsequently purified to homogeneity 
and amino acid sequence derived. Based on this sequence, a full length cDNA was isolated and 
found to encode a novel transmembrane protein, which they termed PZR (Protein Zero Related) 
due to its significant homology to the major structural protein of peripheral myelin, myelin P0. The 
extracellular domain of this protein contains a single extracellular Ig domain and two intracellular 
ITIMs (VIY241AQL and VVY263ADI). Using site-directed mutagenesis, these workers 
demonstrated that these two ITIMs accounted for the entire tyrosine phosphorylation of PZR and 
were essential for SHP-2 recruitment and activation [18]. Like SHPS-1, PZR was found to be 
widely expressed. However, it specifically interacts with SHP-2 but not with SHP-1 [18]. 
In this paper, we describe a unique mAb, WM78, that reacts with the extracellular domain 
of human PZR. Expression cloning using this mAb and RT-PCR analysis have identified two novel 
PZR isoforms, PZRa and PZRb, both lacking ITIM motifs. We further demonstrate the differential 
expression of these isoforms in cells of hematopoietic and mesenchymal origin. Genomic analysis 
and in silico cloning demonstrate that these three isoforms are transcribed from a single gene 
transcription unit on human chromosome 1q24. Interestingly, these novel isoforms differentially 
regulate fibronectin-mediated cell motility in a SHP-2 dependent manner. 
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EXPERIMENTAL 
Cells and WM78 Monoclonal Antibody Generation 
Human hematopoietic cell lines, have been described earlier. HUVEC cells were provided by Drs. 
I. Rappold and M. Raida. Peripheral blood (PB), posterior iliac crest bone marrow (BM) and 
umbilical cord blood (UCB) mononuclear cells were collected with informed consent and ethical 
approval [19-21]. U937 cells were cultured in 10% FCS RPMI-1640 medium containing 10-7 M 
12-O-tetradecanoylphorbol 13-acetate (TPA) (Sigma Chemical Co) as a differentiating agent for 4 
days to induce monocytic differentiation characterised using α-naphthyl acetate non specific 
esterase staining [22]. The WM78 mAb was derived after immunization of BALB/c mice with the 
human T cell line, 8402, and fusion of spleen cells with the SP2/0 myeloma cell line [23].  
Human Bone Marrow Stromal Cell (HBMSC) and Human Bone Marrow Stromal/Osteoblast 
(SOB) Cell Cultures and Magnetic Bead Isolation. 
Stromal cultures were established from BMMNC [24]. Trabecular bone specimens were obtained 
from the Department of Orthopaedic and Trauma, Adelaide Hospital with informed consent and 
institutional ethical approval. Single cells were prepared by collagenase (3mg/ml; collagenase 
Type I; Worthington Biochemical Co., Freehold, NJ) and dispase (4mg/ml; neutral protease grade 
II; Boehringer-Mannheim) treatment. Cell suspensions were analyzed by CD14 and CD45 staining 
(FACS or immunofluorescence) and showed no contamination with macrophages or hematopoietic 
cells [19-21]. BMMNC were incubated with CD34 (561) Dynabeads (Dynal, Oslo, Finland) and 
CD34+ cells captured magnetically and recovered with DETACHaBEADTM reagent (Dynal). 
CD34+ and CD133+ UCB and PB monocytes were also isolated with CD34+, CD133+ or CD14+ 
magnetic beads, respectively (Miltenyi-Biotech, Bergish, Gladbag. Germany) [20, 21]. Isolated 
were labeled with CD34-PE (phycoerythrin), AC133/2-PE or CD14-PE mAbs and were routinely 
>95% pure.  
In Situ Immunofluorescence Staining  
HBMSC cultured in 8-chamber slide flasks (Nunc Inc. Naperville, IL), were fixed in 
acetone/methanol (1:1), blocked with 5% (v/v) normal goat serum (NGS) and stained with the 
WM78 mAb or an isotype-matched mIgG1 control followed by FITC (fluorescein isothiocyanate) - 
conjugated goat anti-mouse F(ab)2 Ig (Silenius, Hawthorn, Vic., Australia) [20]. Cells were 
examined under an Olympus BH2-RFCA fluorescence microscope (Olympus Microsystems, 
London, England). 
Flow Cytometry and sorting 
For single color analyses, cells were stained as described [21]. For dual color analyses, cells were 
labeled with CD4-PE, CD8-PE, CD56-PE or CD19-PE plus biotinylated WM78 mAb and 
streptavidin-FITC or with CD14-FITC, CD45-FITC, CD19-FITC, CD15-FITC or glycophorin A-
Biochemical Journal Immediate Publication. Published on 1 Nov 2002 as manuscript BJ20020935
Copyright 2002 Biochemical Society
 6
FITC, followed by WM78-biotin plus streptavidin-PE or CD3-PE followed by WM78-biotin plus 
streptavidin-FITC [21]. For triple color labeling, cells were stained with CD34-FITC (clone 8G12) 
and CD38-PE (clone HB-7), plus WM78-biotin and streptavidin-tricolor (TC; Caltag Laboratories, 
Burlingame, CA) [20]. BMMNCs were FcR blocked and stained with CD34-PE (clone 8G12) and 
WM78-biotin followed by streptavidin-TC and sorted on the FACStarPLUS (Becton-Dickinson, 
Sunnyvale, CA) [23].  
Clonogenic Assays and Pre-Progenitor Cell (Pre-CFU) Culture  
Cells were assayed for day 14 granulocyte-macrophage (CFU-GM), and/or granulocyte (CFU-G) 
and macrophage (CFU-M) colony forming cells, early erythroid progenitors (BFU-E) and 
multipotential colony forming cell (CFU-Mix) in semi-solid methylcellulose cultures [19, 23]. All 
colonies were scored according to standard criteria after 14 days incubation. Sorted cells were 
cultured in pre-CFU medium containing a cocktail of six haematopoietic growth factors (6HGF) 
rhu IL-1, IL-3, IL-6, G-CSF, GM-CSF and SCF, all at 10 ng/ml, for 28 days [25].  
Immunoprecipitation and SDS –PAGE 
 Goat anti-mouse Ig-coupled Dynabeads (Dynal) were pre-armed with purified immunoglobulin 
(WM78 and isotype matched non-binding controls) as described previously [26]. Samples were run 
on 10% (w/v) SDS-polyacrylamide gel electrophoresis (SDS-PAGE) [27], transferred to polyvinyl-
difluoroacetate membranes (PVDF; MSI Membranes, Bresatec, Adelaide, Australia) and 
developed with streptavidin-alkaline phosphatase (AP; Amersham Int, Little Chalfton, Berks., 
England). Immunoreactive proteins were resolved using a FluorImager and ImageQuant software 
(both from Molecular Dynamics, Sunnyvale, CA). 
Expression Cloning and Sequencing of the WM78 cDNA Clone  
The PZRa cDNA was isolated from a human bone marrow stromal cell (HBMSC) cDNA library in 
the retroviral vector pRUFneo [23] using the WM78 mAb. Following PCR recovery of proviral 
cDNA inserts from genomic DNA, unique Bam HI and Xho I restriction sites present in the 5' and 
3' flanking regions respectively were used to reclone the cDNA into pRUFneo. Stable G418 
resistant Ψ2 virus-producing cell lines were produced by calcium phosphate transfection and used 
to infect FDCP-1 cells by co-cultivation [28]. G418 resistant FDCP-1 cells were analyzed for 
antigen expression by indirect immunofluorescence, flow cytometry and immunoprecipitation as 
above. 
Identification of Full Length PZR, PZRa and PZRb cDNAs and Real Time Quantitative PCR 
Marathon-ready human Burkitt’s lymphoma (Raji cell line) cDNA was purchased from Clontech 
Laboratories Inc., Palo Alto, CA. Total RNAs from cell lines described above, and from normal 
stromal/osteoblast cells, CD133+, CD34+, CD14+ and HUVEC cells, extracted using the RNAzol 
(Biogenesis, Ltd, Poole, England) and the RNA easy (Qiagen Ltd, West Sussex, England) reagents, 
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were reverse transcribed using Sensiscript Reverse Transcriptase system (Qiagen Ltd.). Human 
PZR, PZRa and PZRb were generated by PCR amplification of the cDNAs described above using 
appropriate forward and reverse primers (Sigma Chemical Co.) and the ExpandTM Long PCR 
system (Boehringer-Mannheim) [19]. The cDNAs were ligated into the pGEM-T easy vector 
(Promega) and PCR amplified using the ExpandTM Long Template System (Boehringer-Mannheim) 
and PUC M13 forward and reverse primers [19]. The PZR, PZRa and PZRb PCR products were 
sequenced automatically on an ABI 377 Automatic Sequencer (Perkin-Elmer-Applied Biosystems) 
[19]. Peptide motifs and structural characteristics were predicted using TopPred 2, Das, Signal P, 
TMHMM, O-Glycbase, Net Phos 2.0 Server and MacVector software packages [19].The PZR and 
PZRb TaqManTM (Applied Biosystems) systems consist of the the following pair of primers: FPZR 
(635) T T A A G C A G G C T C C T C G G A G T, RPZR(742) C G G A  G T G G T C T A A C 
T G T G C A T A T A T G and FPZRb (574) A G A A G G A A A A A C T C T A A A C G  G G 
A T T, RPZRb (688) G C A T A C A C C A C A G A C T C T G A C T T G T' respectively as well 
as dual fluorescent probes (PZR: 5'C C C T C C G A C A C T G A G G G T C T T G T A A A G A 
G T C'3 and PZRb: 5'A A C T G T G C A T A T A T G A C T G G G C C C C A G T '3). PZRa 
was not quantified by this method because it was not found in high levels in the majority of cells 
tested and because the sets of primers and fluorescent probes that can be designed in the region that 
distinguish PZRa from the other two isoforms (the 3’ part of exon 4) can amplify genomic DNA. 
The reaction was set up as described in Chiu et al [29]. The difference in the levels of expression 
between PZR and PZRb in different haematopoietic cells was given by the ∆Ct value: ∆Ct=| CtPZR 
- CtPZRb|. The relative expression ratio between the two molecules was calculated using the 
following formula: 2|∆Ct|. All the experiments were carried out in duplicate on 4 independent 
occasions.  
PZR Genomic PAC and Cosmid DNA Clones and Southern Blots  
Three PZRa cDNA probes were used for screening human genomic libraries and subclones and for 
Southern blotting (see Figure 7). Probe A used for screening a human leukocyte PAC library was 
derived from the BamHI/XhoI fragment of PZRa cDNA in the pGEM-T vector. Probe B (366bp), 
used to probe the human chromosome 1 specific cosmid library, was generated by BamHI and Hind 
II digestion of the PZRa cDNA, while probe C was a PCR product generated from the PZRa. Each 
cDNA probe was labeled with 30µCi α-32P-dCTP (Amersham Int.) using the T7 Quickprime kit 
(Pharmacia-Biotech AB) or with the DIG labeling kit (Roche Diagnostics, Mannheim, Germany) 
[19, 20]. The human PAC library was hybridized with α-32P-labeled probe A. Nine positive PAC 
clones identified from these filters or by using the Human Genome Blast program (NCBI Genome 
Sequencing Centre) for PAC clones. 313-L4 PAC clone was selected for further analysis. A human 
chromosome 1 specific cosmid library LLNL Human (HGMP Resource Centre) was probed with 
PZRa probe B. Seven cosmid DNA clones were isolated and then analysed using the PZRa probe B 
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or PCR amplified using a range of primer pairs and the ah95b1 cosmid clone was selected for 
detailed analysis. Human PAC, cosmid and human leukocyte genomic DNA (Promega) samples 
were further analysed using PZRa probes A, B or C (see Figure 7) labeled with α-32P-dCTP or with 
DIG (Roche Diagnostics) [19]. PAC and cosmid DNAs were analyzed by PCR amplification using 
appropriate primers, the ExpandTM Long PCR System (Boehringer Mannheim) and the PCR 
program described above. Human genomic DNA was PCR amplified as above in order to verify the 
PZR genomic sequence in the PAC and cosmid clones. PCR amplification for the GC 5' rich region 
of the gene used the Advantage-GC Genomic Polymerase mix (Clontech Ltd., Cambridge, 
Cambridgeshire, England) with 950C for 1 min. 25 cycles of 940C for 30 secs. and 680C for 12 
mins. and 1 cycle of 680C for 12 mins. The PCR products were isolated by agarose gel 
electrophoresis and ligated into the pGEM-T vector for sequencing. 
Fluorescence in situ Hybridization (FISH) and In silico cloning 
Metaphase spreads were prepared from phytohemagglutinin-stimulated normal human lymphocytes 
probed with the biotinylated ah95b1 cosmid clone as described previously[21]. Neither exon 1 nor 
and the first 1.5 kb of intron 1 were present in the 313-L4 PAC or ah95-b1 cosmid clone sequences. 
Since we located the PZR gene on human chromosome 1q24, and since the Homo Sapiens 
chromosome 1 working draft sequence had been determined by the Sanger Centre and provided by 
the NCBI, the sequence of exon 1 and intron 1 was identified in silico (Genbank database, 
Accession number: NT004668). 
Production of MEF cell lines stably expressing PZR isoforms  
Mouse embryonic fibroblasts (MEFs) were used as SHP-2-/- MEF cells lacking the intact N-SH2 
domain (∆46-110) or as “wild type” (SHP-2 rescue) MEF cells in which the (∆46-110) mutant 
MEF cell line was stably transfected with a competent SHP-2 gene. PZR, PZRa and PZRb were 
RT- PCR amplified from KG1A and HUVEC cells. The cDNAs were digested with BamHI and 
XhoI and subcloned into the multiple cloning site of the pRUF. Neo retroviral vector and  
transfected into the ψ2  [23]. Cells were selected in 400µg/ml G418 prior to transfer into G418 free 
medium DMEM for virus collection and retroviral infection of the MEF cells [23]. Flow cytometry 
and immunoprecipitation identified PZR, PZRb and PZRa proteins of 48, 36 and 34 kD using the 
WM78 mAb (data not shown). The top 50% of the cells expressing PZR were isolated by flow 
sorting as above, cultured in 400µg/ml G418 and used in the migration assay[23]. 
Migration Assay  
The underside of transwell 8µm pore filter was coated in triplicate with either 1 ml of 10µg /ml 
fibronectin  (Boehringer Mannheim) or 10µg/ml BSA as a control, for 2 hours at 370C or overnight 
at 40C. Twenty four hours prior to seeding the cells onto the transwell filter (Costar Corning, NY, 
USA) the cell lines were split 1:2 to ensure log phase growth and 5x104 cells in serum free DMEM 
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added to the upper chamber of the transwells. 500µl of serum free media containing 4µg/ml of 
fibronectin was added to the lower chamber and incubated at 370C for 5 hours. Cells which 
migrated through the filter were fixed in 3.7% (w/v) paraformaldehyde for 10 mins and stained 
with 0.2% (w/v) crystal violet  in ethanol (ICN Biomedicals, Inc., Costa Mesa, CA, USA) for 20 
mins at room temperature Crystal violet was extracted using 300µl of 10% (v/v) acetic acid for 5 
mins at room temperature on a shaker. The results were quantified using a Beckman D4-65 
spectophotometer at 600nm wavelength. Data points derived from 3 independent experiments are 
reported as the mean ± standard error of the mean (SEM). Analysis of the variance to determine 
significant differences between treatments was performed using ANOVA Factorial analyses.  
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RESULTS 
The Monoclonal Antibody WM78 Identifies an Antigen Expressed by Bone Marrow 
Mesenchymal and Peripheral Blood Mononuclear Cells 
The WM78 mAb was selected for its reactivity with bone marrow derived mesenchymal or 
cultured stromal/osteoblast cells (Figure 1a). However, its reactivity was not restricted to these 
cells. Figure 1b illustrates that WM78 binds more strongly to peripheral blood monocytes than to 
granulocytes, platelets and erythrocytes. Indeed, in 3 independent experiments, median 
fluorescence intensities (MFI) of 395.3±55.5 (mean ±S.E.M.) for CD14+ monocytes, 19.8±5.4 for 
CD15+ granulocytes, 16.4±5.4 for CD41b+ platelets and 12.7±4.2 for glycophorin A+ erythrocytes 
were obtained, compared with negative isotype control MFIs of 2.9±0.5, 2.9±0.5, 2.5±0.5 and 
3.4±0.5, respectively. Within the lymphoid compartment, the expression of the WM78 defined 
antigen was variable, ranging from negative or low to strongly positive. Figure 1c illustrates the 
percentage of CD14+ monocytes, CD19+ B cells, CD4+ and CD8+ T cells, and CD56+ NK cells 
staining with WM78. In adult human bone marrow, a similar phenomenon was observed as 
illustrated in Figure 2. 
WM78 Differentially Binds to CD34+ Cell Subsets and Hematopoietic Precursors 
A uniform level of WM78 mAb binding was found on most CD34+ bone marrow precursor cells, 
with 91.9±3.2% (mean ±S.E.M., n=3) of these cells occurring in the CD34+WM78+ gate (Figure 3a 
A). Within this CD34+ population, the CD34+CD38+ cells expressed higher levels of the WM78 
defined antigen than did the more primitive CD34+CD38lo/- subset as determined by three color 
flow cytometric staining (Figure 3a B and C). For example, WM78 MFIs of 54.7±3.5, 22.4±1.5 
and 2.3±0.5 (means±S.E.M., n=3) were obtained for the CD34+CD38+, CD34+CD38lo/- and isotype 
matched negative control subsets, respectively. To confirm that the WM78 mAb bound to 
committed hematopoietic progenitor cells, in vitro clonogenic and pre-CFU assays were performed 
on BMMNC-derived FACS isolated CD34+ (Region R1), CD34+WM78+ (Region R2) and 
CD34+WM78- (Region R3) cells (Figure 3b A). The majority of day 14 BFU-E and CFU-E, were 
recovered in the WM78+CD34+ fraction (Region R2 of Figure 3b A). FACS isolated (Figure 3b A) 
CD34+WM78+ (Region R3) and CD34+WM78- (Region R2) or CD34+ (Region R1) fractions were 
also assayed for de novo generation of nucleated cells in the pre-CFU assay (Figure 3b C). When 
1000 cells were cultured, all the three CD34+WM78+ and CD34+WM78- or CD34+ cell subsets 
were able to generate nucleated cells. 
WM78 Identifies PZRa, a Novel ITIM-less Isoform of the SHP-2 Binding Partner PZR  
 Given its reactivity with a cell surface molecule on cultured human BM stromal cells (Figure 1a), 
the WM78 mAb was used to screen a human bone marrow stromal cell cDNA expression library in 
the retroviral vector pRUF.neo. Automatic sequencing of the resultant cDNA and Genbank/EMBL 
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database analyses revealed substantial nucleotide homology to the previously cloned PZR molecule 
that is expressed in epithelial cells [17]. We named this molecule PZRa (Genbank accession 
number AF181660). Expression of PZRa cDNA in the murine hematopoietic progenitor cell line 
FDCP-1, (Figure 4a B) and immunoprecipitation using the WM78 mAb identified a protein with an 
apparent molecular mass of approximately 30kD (Figure 4b, lane B). Comparative nucleotide and 
predicted amino acid sequences of PZRa with PZR are shown in Figure 5 and demonstrate type 1 
transmembrane molecules with identical extracellular and transmembrane domains but different 
cytoplasmic tails.   
Identification of PZR Isoforms in Hematopoietic, Endothelial and Mesenchymal Cells  
Since our studies revealed that PZR and PZRa contained different cytoplasmic sequences but 
identical extracellular and transmembrane domain sequences, we PCR amplified cDNAs using an 
identical forward primer (FPZR positioned at -17 from the ATG) but different reverse primers to 
sequences in the 3' UTRs that would specifically distinguish between PZR and PZRa gene 
products, namely R904 and R974 repsectively (Figure 5). Initial PCR analyses, using these primer 
pairs with the Raji and KG1A cDNAs, generated three rather than two different products. One 
product of approximately 650 bp produced with the primer pair, FPZR and R904, was detected 
only after 60 cycles of PCR amplification and was identical to the PZRa sequence (Figure 5). The 
other two products that were generated using the primer pair FPZR and R974 were approximately 
900 and 700 bp in size and were generated with 30 cycles of PCR amplification (Figure 6a). 
Sequence analysis demonstrated that the larger product was identical to PZR (Figure 5) whereas the 
smaller product was identical to PZR in its extracellular and transmembrane domains, but not in its 
cytoplasmic tail. We have termed this product, PZRb (Figure 5). Further RT-PCR analysis revealed 
that the PZR and PZRb isoforms are widely expressed in the hematopoietic progenitor cells and 
cell lines examined (Figure 6a). Using real-time quantitative PCR, it was found that PZR and PZRb 
were present in almost equivalent amounts in CD14+ peripheral blood monocytes and in cell lines 
representing pre B (RPMI-1788). However, PZRb appeared to be the major isoform in CD34- 
promyelocytic (HL60) and promonocytic (U937) cell lines (7.31 and 7.11 fold higher expression, 
respectively than PZR) and in multipotent progenitor cells (KG1A). Differentiation of U937 cells 
along the monocytic lineage revealed a decrease in PZRb and an increase in PZR expression. 
Interestingly, PZR was prominent in stromal cells (23.1 fold higher than PZRb) and to a lesser 
extent in human umbilical vein endothelial cells (HUVEC) and in erythroid progenitors (K562) 
(Figure 6b). The PZRa isoform was expressed at significant levels (i.e. using 30 cycles of RT-PCR 
amplification) in the erythroid progenitor cell line K562, but was detected only after 60 PCR cycles 
and therefore at putatively low levels in KG1A and Raji cells (Figure 6a and data not shown). The 
differential distribution of the PZR isoforms in different cell types suggests that a mechanism exists 
for controlling PZR isoform expression and hence function during lineage development or 
commitment within the hematopoietic, mesenchymal and vascular systems. Since FACS analysis 
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(see Figures 1 to 3) revealed that WM78 binds strongly to mesenchymal derived cells and to a 
variety of hematopoietic cells and their progenitors, we immunoprecipitated the WM78 defined 
molecule from human bone marrow stromal/osteoblast (SOB) cells (Figure 6c, lane D), bone 
marrow CD34+ cells (Figure 6c, lane E) and the erythroid progenitor cell line K562 (Figure 6c, lane 
F). The results demonstrated the presence of multiple protein bands on SDS-PAGE gels under 
reducing conditions. A major band with an apparent molecular mass of approximately 32-36 kD 
was found in the SOB cell lysate and was weakly detectable in K562 cells, which like bone marrow 
CD34+ progenitor cell lysates, produced a main band at approximately 36-48kD. The latter is 
identical to the molecular mass previously identified for PZR in transfected cells [17], while the 
former 32-36kD band in SOB cells is likely to represent PZRb. These studies suggest that the 
different PZR isoforms are differentially expressed in hematopoietic and mesenchymal derived 
cells. 
Amino acid Sequence Identity and Potentially Important Motifs for the PZR Isoforms 
The amino acid sequence similarities and predicted structures of the three PZR-like peptides are 
shown in Figures 5, 6d and e respectively. PZRa, PZRb and PZR cDNAs are predicted to encode 
type 1 transmembrane proteins of 202, 209 and 269 amino acids, respectively. In all three isoforms, 
the predicted signal peptide cleavage site is positioned between Arg 37 and Leu 38 (VSA-LE). An 
IgV-set domain motif linked by disulfide bridges is predicted to occur between amino acids 58 and 
135, placing these molecules in the immunoglobulin (Ig) superfamily. Each PZR isoform contains 
two potential N-linked glycosylation sites (at Asp 50 and Asp 130) and three potential O-linked 
glycosylation sites at Thr 70 and on Ser residues 70 and 75. A 27 amino acid transmembrane 
hydrophobic sequence lies between amino acids 162 and 189. PZR possesses the longest 
intracellular domain of 80 amino acids, and contains a classical ITIM motif of the type 
(V/I)XYXX(L/V) and more specifically VIY246AQL and VVY263ADI (246 and 263 tyrosine 
phosphorylation sites) that has previously been shown to interact with the SH2 domains of SHP-2 
[17, 18]. The cytoplasmic domains of PZRa and PZRb are truncated to 13 and 20 amino acids 
respectively with both lacking the classical ITIM motif and SHP-2 binding sites. Database analyses 
revealed one potential tyrosine phosphorylation site at position 200 of the amino acid sequences in 
both PZRa and PZRb molecules. PZR isoforms show significant amino acid similarity with myelin 
Po protein and epithelial V-like antigen 1 (Figure 6e).  
Genomic Structural Analyses Reveal that the PZR Isoforms are Derived by Differential 
Splicing of a Single Gene Transcription Unit and are Located on Human Chromosome 1q24 
To determine if the PZR isoforms are products of one or more genes, we analyzed the genomic 
structure. The 313-L4 PAC clone (Genbank Accession number: Z99943) provided a partial 
sequence for the PZR gene that we predict encompasses part of intron 1 and exons 2 to 6 but lacks 
the 5' region encompassing the signal sequence and 5' that would exon 1. The exon 1 and intron 1 
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sequences (GenBank Accession number: NT004668) were identified using an in silico cloning 
strategy. Comparative analyses of the genomic sequence with PZR, PZRa and PZRb cDNAs 
indicated that these isoforms are derived by differential splicing of exons from a single gene 
transcription unit (Figure 7b). The region spanning the coding exons 1 to 6 covers at least 66 kb of 
genomic DNA. While the PZR isoforms are identical from exon 1 to 4, the sequences of the 
isoforms diverge in subsequent exons. The signal peptide is encoded by exon 1 and part of exon 2, 
while the extracellular region is encoded by exons 2 and 3 and part of exon 4 (111- 482 nt). The 
transmembrane sequence is encoded by exon 4 (483-567 nt). For the PZRa transcript, exon 4 
begins at +473 bp from the ATG of the translational start site with a TAA stop codon at bps  +607 
to +609. This is followed by a 3' UTR sequence of at least 541bp. Similarly, for both the PZR and 
PZRb transcripts, exon 4 starts at +473 bp and reads through to +605 bp. However, unlike PZRa, 
both PZR and PZRb then use a dinucleotide GT splice site one base before the stop codon of PZRa 
to splice onto additional exons. PZR splices onto exon 5, which comprises 103 bps and covers +606 
to +705 bps of the mRNA sequence, which then splices onto exon 6 which encompasses +706 to 
+1019 bps, with a TAA stop codon located at +808 to +810 bps. PZRb splices from exon 4 onto 
exon 6 at +606 bp but reads through to a TAG stop codon at +628 bp. From the cDNA sequence, 
we would predict a minimum 3' UTR sequence of 123 bp. Metaphase spreads were examined using 
the 95b1 cosmid clone containing the PZR gene as a probe. Positive signals were observed on both 
chromatides of human chromosome 1 at band 1q24 (Figure 8). 
PZR, but not PZRa or PZRb, Regulates Integrin-Mediated Cell Motility 
 Stable transfectants were analysed for their relative expression levels of the PZR isoforms using 
flow cytometry with the WM78 mAb. A representative set of histograms (Figure 9a) shows a 
relatively uniform mean fluoresence intensity for each of the transfectants. Using these cells, we 
investigated the effects of SHP-2 depletion in relation to PZR and its various isoforms on migration 
over the extracellular matrix protein, fibronectin. Previous studies have indicated that the SHP-2 
mutant cells (∆46-110) migrate at a slower rate than the SHP-2 rescue cells [30] and that the mutant 
SHP-2 protein without the intact N-SH2 domain (∆46-110) does not function in a dominant 
negative manner but rather as a loss-of-function molecule [14]. Thus, the availability of the SHP-2 
rescue, “wild type” fibroblast cell line, where SHP-2 had been re-introduced into SHP-2-/- cells 
together with the homozygous SHP-2-/- mutant (∆46-110) fibroblast cell line, provided us with a 
unique opportunity to study PZR-mediated effects in a SHP-2 positive or negative background. 
Using a transwell migration chamber with 8µm pores, the migration of uninfected wild-type and 
SHP-2 -/- (∆46-110) MEF cells was compared with the migration of the PZR isoform expressing 
MEF cell lines on BSA or fibronectin. As shown in Figure 9b, no significant migration was 
observed using BSA as the chemotactic stimulus. In contrast, in 3 independent experiments, 
migration was increased to variable levels with all cell lines using fibronectin as the integrin-
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mediated stimulus. Importantly, a two to five-fold enhancement in migration was observed in the 
wild-type PZR-rescue MEF cell line compared to other PZR isoforms in SHP-2 rescue and mutant 
MEF cell lines. These results demonstrate that the intact PZR cytoplasmic domain containing the 
ITIM-motifs is important in modulating fibronectin-mediated cell migration rates, in these murine 
mesenchymal derived MEF cells. 
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DISCUSSION 
PZR has previously been identified as a SHP-2 binding partner in epithelial cells [17]. In 
this paper, we report the identification and cloning of two novel isoforms of PZR, PZRa and PZRb, 
and demonstrate that these three isoforms are differentially expressed in the hematopoietic lineage 
and in stromal/mesenchymal cells. Of particular interest is the observation that the PZR isoforms 
are more strongly expressed on CD34+CD38+ clonogenic haematopoietic precursors than in more 
primitive CD34+CD38lo/- pre-CFU precursors. Furthermore, PZR predominates over PZRb in 
endothelial cells. In addition, a switch occurs during monocytic differentiation when the ratio of 
PZR increases relative to PZRb. In mesenchymal cells and osteoblasts, PZR is the major isoform. 
The significance of the alteration in expression of the PZR isoforms during monocytic 
differentiation appears to be related to the structural differences between the different isoforms. 
While all three isoforms possess identical extracellular and transmembrane sequences, only the 
PZR isoform contains a cytoplasmic tail with two ITIM motifs (VIY246AQL and VVY263ADI) that 
can specifically interact with SH2 domains of SHP-2 [17]. This in turn may endow PZR, but not 
PZRa or PZRb, with a negative SHP-2 regulatory role in these cells. It further implies that the 
differential expression of PZR isoforms may differentially modulate signaling pathways that 
involve SHP-2 in different cell types. During the preparation of this manuscript Zhao et al. [31] 
demonstrated that truncation of the intracellular domain of PZR blocks ConA induced PZR tyrosine 
phosphorylation in epithelial cells. A similar phenomenon may occur during myeloid 
differentiation from multipotent progenitors when a switch from PZR to PZRb occurs. We have 
demonstrated that PZR isoforms are generated by differential splicing of a single gene transcription 
unit on human chromosome 1q24. Other ITIM containing IgSF members (e.g. KIRS, 
ILTs.LIRs/MIRs, LAIR-1 and NKp46, CEACAMs and Siglecs) with both IgV and IgC2 domains 
are concentrated on human chromosome 19, while those with a single IgV domain (e.g. Myelin P0, 
PD-1, CMRF-35 and NKp44) like PZR are distributed across chromosomes 1, 2, 6 and 7 [32]. 
Interestingly, the PZR gene is closely linked to molecules (e.g myelin P0) on chromosome 1 with 
which it shares homology, suggesting that these molecules may have similar or related functions. It 
has been suggested recently that myelin P0 has a crucial role myelin production, with mutations in 
the myelin P0 extracellular, transmembrane or ITIM regions leading to inherited neuropathies (e.g. 
Dejerine-Sottas syndrome and Charcot-Marie-Tooth disease) [33, 34]. Similar mutations in PZR 
resulting in human disease have not been identified. 
SHP-2 plays a critical role in haematopoietic and vascular development. Whether SHP-2 
expresses its function in stem/progenitor cell or mesenchymal/osteoblast proliferation, survival, 
migration or differentiation is not fully established. The identification of its interacting partners and 
their mechanisms of action is therefore of major importance in determining its function and that of 
the PZR isoforms. Those partner molecules identified to date include certain cytokine receptors and 
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integrins [8, 9, 35]. SHP-2 physically interacts with and is tyrosine phosphorylated by the c-kit 
receptor tyrosine kinase upon of SCF ligand binding to hematopoietic and embryonic stem (ES) 
cells [36]. Treatment of ES cells with SCF induces Erk kinase activation, but this induction is 
completely blocked in shp-2 -/- ES cells. SHP-2 also interacts with the common gp130 subunit of 
the IL-6, LIF and oncostatin M receptors [8, 12]. Thus, mutant ES cells lacking the SHP-2 binding 
site in either SHP-2 or gp130 have impaired abilities to differentiate in vitro [37]. It has also been 
shown that SHP-2 has an important role in cell motility. Shp-2 mutant cells have defects in 
migration as well as spreading and have an increased number of focal adhesions [38]. Dominant 
negative SHP-2 expression blocks FGF- induced elongation of Xenopus animal caps and prevents 
completion of gastrulation [2, 39]. A positive-feed back model is also suggested, in which integrin 
engagement induces c-Src to catalyze the tyrosyl phosphorylation of SHP-2 substrates, thereby 
recruiting SHP-2 to the plasma membrane. By further activating Src PTKs, SHP-2 transduces 
positive signals for downstream events such as MAPK activation and this alters cell shape [2]. 
Whether the ITIM-containing PZR, or PZRa and PZRb ITIM-less isoforms have a function 
in modulating these cytokine and adhesive responses has been a matter of speculation. We would 
predict that PZR, because of its distribution pattern, acts as a docking molecule for SHP-2 and 
prevents or rapidly down-modulates cytokine receptor and integrin interactions with SHP-2, 
following binding of their ligands. PZRa and PZRb, on the other hand, may act as activating 
molecules for ITAM containing partners. This would be reminiscent of the SIRP family of 
molecules, which consist of two subtypes distinguished by the presence (SIRPα) or absence 
(SIRPβ) of a cytoplasmic ITIM domain. Overexpression of SIRPα1 leads to the inhibition of cell 
activation induced by insulin, epidermal growth factor and platelet derived growth factor [40, 41]. 
It has also been shown that SIRPα1 can positively regulate the mitogen activated protein kinase 
(MAPK) signaling pathway in response to insulin and potentiate integrin-induced MAPK activation 
[42-44]. In contrast, SIRPβ1 physically associates with the killer cell activating receptor-associated 
protein (KARAP)/DAP-12 resulting in the functional coupling of SIRP1β to the protein tyrosine 
kinase Syk and to serotonin release and activation of the cells [45]. Alternatively, the PZRa and 
PZRb ITIM-less isoforms could directly interact with PZR and inhibit the ability of PZR to interact 
with SHP-2. In this paper, we have clearly demonstrated the importance of SHP-2 in regulating cell 
motility in our Boyden chamber transwell assays. In general, mutant SHP-2 (∆46-110) displayed a 
decreased capacity to migrate in comparison to the rescue SHP-2 cell lines. Interestingly, the SHP-
2 rescue cells expressing the full-length PZR isoform exhibited a five fold increase in their capacity 
to migrate on fibronectin. This is of particular interest since the full length PZR isoform contains 
tandem ITIMs that act as a docking site for SHP-2. Recent studies show that SHP-2 is involved in 
the deactivation of focal adhesion kinase (FAK) which is required for the generation of active FAK 
in the turnover of focal adhesions during migration [30]. SHP-2 also negatively regulates signaling 
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pathways that promote migration by reducing integrin-mediated adhesion. Thus, integrin 
engagement by fibronectin may lead to tyrosine phosphorylation of PZR, and recruitment and 
activation of SHP-2, which then induces dephosphorylation events to induce turnover of focal 
adhesions, reduced adhesion and increased cell motility. Our studies, therefore indicate that the 
cytoplasmic region of PZR containing ITIMs plays an important role in regulating integrin-
mediated cell motility and that truncated forms of PZR lacking ITIMs fail to regulate cell motility. 
Recent studies [31] also indicate that PZR is a receptor for ConA on epithelial cells and that 
expression of a truncated form of PZR in an epithelial cell line is able to inhibit ConA-induced 
tyrosine phosphorylation of PZR. Our unique WM78 mAb has the ability to bind and tyrosine 
phosphorylate PZR (our unpublished data) and is undoubtedly more specific for PZR than ConA. 
Such a mAb will be useful for studying PZR specific activation both in haematopoietic and 
epithelial cells and may have therapeutic applications. A detailed analysis of the mechanisms of 
action of the PZR isoforms and of the WM78 mAb will therefore be the subject of further 
publications and experimentation.  
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                                                                     Isotype Control or WM78 FLUORESCENCE 
(c)    
Percentage WM78 Positive Cells in each Subset after gating against a Negative Isotype 
Control 
Cellular subset Percentage Positive 
Mean  ± SEM (n=3) 
CD14+ monocytes 99.3±1.2 
CD15+ granulocytes 42.5±12.6 
CD19+ B cells 75.6±18.4 
Glycophorin A+ erythrocytes 73.2±23.2 
CD4+ T cells 41.1±10.3 
CD8+ T cells 38.2±6.2 
CD41b+ platelets 57.9±13.2 
CD56+ natural killer cells 49.9±15.3 
 
Figure 1: The WM78 mAb identifies an antigen on cultured human bone marrow SOB and 
peripheral blood cells  
Single color flow cytometry showing binding of the mAb WM78 (bold histograms) to cultured 
human bone marrow SOB cells (a). Representative histograms of peripheral blood myeloid subsets 
gated for CD14, CD15, CD41b or anti-glycophorin positive cells prior to analysis with the isotype 
matched negative control (non-bold histograms) or the WM78 mAb (bold histograms) (b). The 
non-binding, isotype matched mIgG1 negative control mAb was 1B5 (non-bold histograms). The 
anti-HLA Class I mAb was used as the positive control (a). M1 marks the position of the positive 
gate used to determine the % positive cells in each subset. (c) The table shows the percent of each 
peripheral blood cell subset that stains with WM78 after gating against a negative isotype control. 
Values are mean ± SEM for 3 independent experiments. 
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 (b) 
 
Percentage WM78 Positive Cells in each Subset after gating against a Negative Isotype 
Control 
Cellular subset Percentage Positive 
Mean ± SEM (n=3) 
CD14+ monocytes 54.9±18.5 
CD15+ granulocytes 23.3±3.2 
CD19+ B cells 69.6±3.3 
Glycophorin A+ erythrocytes 12.7±4.0 
CD3+ T cells 14.9±5.9 
CD45+ leukocytes 14.1±5.5 
 
Figure 2: Differential binding of the WM78 mAb to human bone marrow hematopoietic cell subsets.
Representative two-colour dot plots demonstrating the differential binding of CD markers and the WM78
mAb to BMMNC (a). The cells were labeled with FITC conjugated lineage specific markers and biotin
conjugated WM78 mAb plus PE-streptavidin. Mouse IgG1 mAbs conjugated with PE, FITC or biotin
were used as negative controls. The % in each quadrant represents the percentage of BMMNC staining
with the mAbs indicated. (b) cells were gated for each of the positive CD markers separately and the
relative percentage of CD14+, CD45+, CD3+, CD19+, CD15+ and glycophorin A+ cells staining with
WM78 determined. Values are mean ± SEM for 3 independent experiments. 
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Figure 3: The WM78 mAb binds differentially to CD34+CD38+ and CD34+CD38lo/- subsets 
and to hematopoietic progenitor cells.  (a) A typical two-colour dot plot of BMMNC labeled with 
WM78-biotin plus streptavidin-Tricolour, CD34-FITC and CD38-PE (A), CD34-PE, CD38-FITC 
and WM78-biotin plus streptavidin-Tricolour (B) and WM78-biotin plus streptavidin-Tricolour, 
CD38-FITC and CD34-PE (C). The relative CD38 staining of cells in the CD34+WM78+ and 
CD34+WM78lo/- (A) and the relative WM78 staining of cells in CD34+CD38+ and CD34+CD38lo/- 
fractions (B) were determined by flow cytometry as median fluorescence values (MFI) for 3 
independent samples. (b) A: A representative dot plot of BMMNC labeled with WM78-biotin plus 
streptavidin-PE and CD34-FITC and flow sorted into the CD34+ (Region R1), CD34+WM78+ 
(Region R2) and CD34+WM78- (Region R3) subsets, showing the percentages in each quadrant. B: 
Clonogenic cells were measured from sorted fractions, R1, R2 and R3, and analyzed for the 
presence of day 14 multipotential, erythroid and myeloid progenitor cell  [Solid (CFU-GM), open 
(CFU-G), left hatched (CFU-M), stippled (BFU-E) and right hatched (CFU-Mix)]. Results (means 
± S.E.M. from 3 donors R, B and Z) are expressed as the recovered clonogenic cells in fractions R2 
and R3 on the basis of the percentage of WM78+ or lo/- cells in the CD34+ fraction R1 and after 
normalization of values for clonogenic cell output to the CD34+ subset to 100%. C: Cells from 2 
donors B and Z sorted into fractions R1, R2 and R3 were also assayed for their content of pre-CFU 
as described in the Materials and Methods. Data represent the fold expansion of nucleated cells 
after 1000 cells from each fraction was cultured in 6HGF for up to 35 days.  
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Figure 4: Identification of PZRb. (a) After expression cloning, PZRa cDNA was transfected into 
FDCP-1 cells and analyzed by flow cytometry for cell surface binding of the WM78 mAb or a 
mIgG1 isotype matched negative control (B). The histograms in (A) represents sham transfected 
FDCP-1 cells labeled with mIgG1 or WM78 mAbs. (b) Immunoprecipitation of the PZRa molecule 
using mIgG1 (lanes A and C) or the WM78 mAb (lanes B and D) from FDCP-1 cells expressing 
PZRa (lanes A and B) or in non–expressing FDCP-1 cells (lanes C and D) and analysis by 10% 
SDS-PAGE.  
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Figure 5: Comparative cDNA and amino acid sequences of PZR isoforms. The PZR cDNA 
sequence was obtained by RT-PCR analyses using primers indicated. The extracellular, the 
transmembrane and the intracellular domains are indicated by bold italics, underlined, and bold 
respectively. Cysteines are circled and tyrosine residues are marked in a square. Potential N- and 
O- linked glycosylation sites are indicated by * and # respectively. Differences between the 
cytoplasmic domains of PZR, PZRa and PZRb isoforms are dot underlined and identities in the 3' 
region between PZR and RZRb are double underlined. The positions of FPZR, R904 and R974 
primers are highlighted. The additional 5' UTR and 3' UTR sequences of PZRa were identified 
from the PZRa cDNA sequence. The 3' UTR sequence of PZR was obtained from the published 
sequence (Gene Bank Accession number: AF087020).  
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Figure 6: Distribution of hematopoietic endothelial and mesenchymal derived cells for PZR 
isoforms. (a) The distribution of PZR isoforms was examined by RT-PCR analysis in KG1A, KG1, 
HL60, U937, K562, RPMI-1788 as well as HUVEC, normal CD133+ progenitor cells (95% purity), 
CD14+ peripheral blood monocytes (86% purity) and cultured bone marrow SOB. (b) Real-Time 
Quantitative PCR. Fold expression of PZR versus PZRb is presented. Values are means of 4 
independent experiments ±S.D. as calculated in Materials and Methods. (c) Immunoprecipitation of 
PZR isoforms from human bone marrow cultured stromal / osteoblast cells (lane D), CD34+ cells 
(lane E) and the erythroid precursor cell line K562 (lane F) with the WM78 mAb and the respective 
negative controls  (lanes A, B and C) and electrophoresis on 10% SDS-PAGE. Arrows indicate the 
positions of the predicted PZR and PZRb isoforms. Seablue II markers (Navex, Invitrogen, CA, 
USA) were used. (d) shows a schematic representation of PZR isoforms. (e) The percent amino 
acid identities and similarities between PZR and PZRa, PZRb, myelin P0 and epithelial V-like 
antigen are listed. 
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Figure 7: PZR genomic structure. (a) PZRa probes used for screening PAC and cosmid libraries. 
(b) schematic representation of the genomic structure of PZR gene showing exons 1 to 6 (boxed) 
and introns 1 to 5 (line). Sequences encoding the different domains (signal peptide (SP), 
extracellular (ED), transmembrane (TD) and cytoplasmic (cyt1, cyt2, cyt3) domains for PZR, PZRa 
and PZRb mRNAs are shown. 
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Figure 8: The PZR gene is located on human chromosome 1q24. (a) FISH analysis using the 
ah95b1 cosmid clone as a probe shows that PZRa, PZRb and PZR isoforms are located on human 
chromosome 1q24. (b) An ideogram of human chromosome 1 showing the localization of the PZR 
gene to band q24. 
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Figure 9: Cell motility regulated by PZR isoforms. (a) Surface expression of PZR isoform-
expressing SHP-2 rescue (“wild type”) and SHP-2 mutant (∆46-110) MEF cell lines used in the 
assays. Cells were stained with 10 µg/ml of the PZR-specific mAb WM78 (white profile) or 
isotype control 1B5 (grey profile). Specific staining was detected after incubation with saturating 
levels of FITC-conjugated sheep anti-mouse Ig. These profiles show a comparable level of PZR 
expression for each of the different isoforms. (b) The effect of PZR isoforms on migration of SHP-
2 rescue “wild type” (Res) and SHP-2 mutant (∆46-110) (Mut) cell lines was assessed by the 
Boyden transwell assay. The cells stably transduced with various isoforms of PZR specified or non 
- transfected cells (UT) were seeded on 8 µm porous membranes coated with either BSA or 
fibronectin (FN) in Boyden multiwell chambers. Following incubation for 5 hrs at 37°C, cells 
which had migrated through the membrane were quantitated by crystal violet staining and 
spectrophotometry 600nm. A significant difference (p<0.005, Anova) in the migration potential 
was conferred to cells expressing the ITIM-containing isoform of PZR. The results represent the 
mean ± SEM of 3 independent experiments. 
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